Origar Beta News Today

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023

Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an... | May 1, 2023

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...

Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not ap...

Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24 Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc....